<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>ulcerative colitis; PREDICTORS; Biosimilar; CT-P13; Crohn’s disease; Long-term efficacy | Ferenci Tamás honlapja</title><link>https://www.medstat.hu/tag/ulcerative-colitis-predictors-biosimilar-ct-p13-crohns-disease-long-term-efficacy/</link><atom:link href="https://www.medstat.hu/tag/ulcerative-colitis-predictors-biosimilar-ct-p13-crohns-disease-long-term-efficacy/index.xml" rel="self" type="application/rss+xml"/><description>ulcerative colitis; PREDICTORS; Biosimilar; CT-P13; Crohn’s disease; Long-term efficacy</description><generator>Wowchemy (https://wowchemy.com)</generator><language>hu</language><lastBuildDate>Sun, 01 Jan 2017 00:00:00 +0000</lastBuildDate><image><url>https://www.medstat.hu/media/sharing.png</url><title>ulcerative colitis; PREDICTORS; Biosimilar; CT-P13; Crohn’s disease; Long-term efficacy</title><link>https://www.medstat.hu/tag/ulcerative-colitis-predictors-biosimilar-ct-p13-crohns-disease-long-term-efficacy/</link></image><item><title>Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center</title><link>https://www.medstat.hu/publication/mtmt-3269325/</link><pubDate>Sun, 01 Jan 2017 00:00:00 +0000</pubDate><guid>https://www.medstat.hu/publication/mtmt-3269325/</guid><description/></item></channel></rss>